These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33789628)

  • 1. Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study.
    Kim SR; Hong JH; Sung SY; Kim YH; Chun SH; Lee HW; Lee JS; Ko YH
    BMC Cancer; 2021 Mar; 21(1):340. PubMed ID: 33789628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.
    Yu TT; Hu X; Liufu WJ; Niu SQ; Lian HM; Ma HL; Wang J; Bao Y; Chen M; Peng F
    Cancer Med; 2024 Apr; 13(8):e7215. PubMed ID: 38659392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database.
    Lee JS; Kim S; Sung SY; Kim YH; Lee HW; Hong JH; Ko YH
    Front Oncol; 2021; 11():546672. PubMed ID: 33828968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of EP Chemotherapy Followed by IP Chemotherapy Combined with Radiotherapy in the Treatment of Extensive-Stage Small-Cell Lung Cancer.
    Kang S; Lai CORXWZJHYZDCJ
    J BUON; 2021; 26(2):306-312. PubMed ID: 34076973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of limited-stage small cell lung cancer with comprehensive treatment including radical resection.
    Zhong L; Suo J; Wang Y; Han J; Zhou H; Wei H; Zhu J
    World J Surg Oncol; 2020 Feb; 18(1):27. PubMed ID: 32013993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer].
    Wang D; Xu L; Zhao L; Zhang W; Pang Q; Liu N; Chen X; Chen X; Yuan Z; Wang P
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):871-878. PubMed ID: 27978874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
    Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
    Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
    Wang C; Zhu S; Miao C; Wang Y; Chen J; Yuan S; Hu X
    BMC Cancer; 2022 May; 22(1):542. PubMed ID: 35562713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.
    Verma V; Moreno AC; Haque W; Fang P; Lin SH
    J Natl Compr Canc Netw; 2018 May; 16(5):508-516. PubMed ID: 29752325
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
    Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
    Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer.
    Han D; Qin Q; Hao S; Huang W; Wei Y; Zhang Z; Wang Z; Li B
    Radiat Oncol; 2014 Dec; 9():280. PubMed ID: 25498196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.
    Zhao S; Chen K; Shi X; Sun J; Fang W; Huang Y; Zhang L
    Clin Lung Cancer; 2023 Nov; 24(7):e254-e258. PubMed ID: 37442748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
    Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.